AngelMed completes its first USA commercial Guardian implant
Filed with ASX · · 2 pages · English
The outpatient procedure was successfully performed last week by cardiac electrophysiologist and cardiologist Dr. Andrew J. Kaplan of Cardiovascular Associates of Mesa in Mesa, Arizona. Dr. Kaplan is a pioneer of new cardiac technologies and has played a significant role in The Guardian's commercialisation. The procedure marks The Guardian's first use following recent FDA approval. Indicated for a
Story so far
Earlier from Hydrix
- Hydrix completes TGA submission for AngelMed Guardian System
- Investor Presentation - AngelMed Guardian FDA Approval
- AngelMed receives FDA approval for Guardian upgraded battery
- 2020 AGM - Executive Chairmans Presentation
- First in human trials of Phyzhon Health PHYRARI FFR-WIRE
Later from Hydrix
- Commercial arrangement between Hydrix and Memphasys
- FY2021 Letter from Executive Chairman
- FY2021 Appendix 4E and Financial Report
- MEM: Reaches settlement agreement with Hydrix
- Quarterly Activities Report
Follow Hydrix into a list and get an email when it puts out news.
Follow Hydrix